Reprofiled drug targets ancient protozoans

References

• Vaidya AB, Ray DK. Amoebiasis: the tropical scourge. Science Today (India) 1982 pp. 21-26.
   Google Scholar
• Cox FE. History of human parasitology. Clin Microbiol Rev 2002; 15:595 - 612; http://dx.doi.org/10.1128/CMR.15.4.595-612.2002; PMID: 12364371
   PubMed Web of Science ®Google Scholar
• Tanyuksel M, Petri WA Jr.. Laboratory diagnosis of amebiasis. Clin Microbiol Rev 2003; 16:713 - 29; http://dx.doi.org/10.1128/CMR.16.4.713-729.2003; PMID: 14557296
   PubMed Web of Science ®Google Scholar
• Ortega YR, Bonavia D. Cryptosporidium, Giardia, and Cyclospora in ancient Peruvians. J Parasitol 2003; 89:635 - 6; http://dx.doi.org/10.1645/GE-3083RN; PMID: 12880276
   PubMed Web of Science ®Google Scholar
• Allison MJ, Bergman T, Gerszten E. Further studies on fecal parasites in antiquity. Am J Clin Pathol 1999; 112:605 - 9; PMID: 10549246
   PubMed Web of Science ®Google Scholar
• WHO/PAHO/UNESCO report.. WHO/PAHO/UNESCO report. A consultation with experts on amoebiasis. Mexico City, Mexico 28-29 January, 1997. Epidemiol Bull 1997; 18:13 - 4; PMID: 9197085
   PubMedGoogle Scholar
• World Health Organization. The World Health Report 1998: life in the 21st century: a vision for all. Geneva: World Health Organization. 1998.
   Google Scholar
• Adam RD. Biology of Giardia lamblia. Clin Microbiol Rev 2001; 14:447 - 75; http://dx.doi.org/10.1128/CMR.14.3.447-475.2001; PMID: 11432808
   PubMed Web of Science ®Google Scholar
• Wright JM, Dunn LA, Upcroft P, Upcroft JA. Efficacy of antigiardial drugs. Expert Opin Drug Saf 2003; 2:529 - 41; http://dx.doi.org/10.1517/14740338.2.6.529; PMID: 14585063
   PubMedGoogle Scholar
• Fletcher SM, Stark D, Harkness J, Ellis J. Enteric protozoa in the developed world: a public health perspective. Clin Microbiol Rev 2012; 25:420 - 49; http://dx.doi.org/10.1128/CMR.05038-11; PMID: 22763633
   PubMed Web of Science ®Google Scholar
• Cabada MM, White AC Jr.. Treatment of cryptosporidiosis: do we know what we think we know?. Curr Opin Infect Dis 2010; 23:494 - 9; http://dx.doi.org/10.1097/QCO.0b013e32833de052; PMID: 20689422
   PubMed Web of Science ®Google Scholar
• Savioli L, Smith H, Thompson A. Giardia and Cryptosporidium join the ‘Neglected Diseases Initiative’. Trends Parasitol 2006; 22:203 - 8; http://dx.doi.org/10.1016/j.pt.2006.02.015; PMID: 16545611
   PubMed Web of Science ®Google Scholar
• Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. Drugs 1997; 54:679 - 708; http://dx.doi.org/10.2165/00003495-199754050-00003; PMID: 9360057
   PubMed Web of Science ®Google Scholar
• Fung HB, Doan TL. Tinidazole: a nitroimidazole antiprotozoal agent. Clin Ther 2005; 27:1859 - 84; http://dx.doi.org/10.1016/j.clinthera.2005.12.012; PMID: 16507373
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 2001; 184:381 - 4; http://dx.doi.org/10.1086/322038; PMID: 11443569
   PubMed Web of Science ®Google Scholar
• Bendesky A, Menéndez D, Ostrosky-Wegman P. Is metronidazole carcinogenic?. Mutat Res 2002; 511:133 - 44; http://dx.doi.org/10.1016/S1383-5742(02)00007-8; PMID: 12052431
   PubMed Web of Science ®Google Scholar
• Sweetman SC. Martindale: The Complete Drug Reference, 33rd ed. Pharmaceutical Press, London, 2002:594.
   Google Scholar
• Wassmann C, Hellberg A, Tannich E, Bruchhaus I. Metronidazole resistance in the protozoan parasite Entamoeba histolytica is associated with increased expression of iron-containing superoxide dismutase and peroxiredoxin and decreased expression of ferredoxin 1 and flavin reductase. J Biol Chem 1999; 274:26051 - 6; http://dx.doi.org/10.1074/jbc.274.37.26051; PMID: 10473552
   PubMed Web of Science ®Google Scholar
• Upcroft P, Upcroft JA. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin Microbiol Rev 2001; 14:150 - 64; http://dx.doi.org/10.1128/CMR.14.1.150-164.2001; PMID: 11148007
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide. J Infect Dis 2001; 184:103 - 6; http://dx.doi.org/10.1086/321008; PMID: 11398117
   PubMed Web of Science ®Google Scholar
• Abdulla MH, Ruelas DS, Wolff B, Snedecor J, Lim KC, Xu F, et al. Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl Trop Dis 2009; 3:e478; http://dx.doi.org/10.1371/journal.pntd.0000478; PMID: 19597541
   PubMedGoogle Scholar
• Debnath A, Parsonage D, Andrade RM, He C, Cobo ER, Hirata K, et al. A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat Med 2012; 18:956 - 60; http://dx.doi.org/10.1038/nm.2758; PMID: 22610278
   PubMed Web of Science ®Google Scholar
• von Oettingen J, Nath-Chowdhury M, Ward BJ, Rodloff AC, Arrowood MJ, Ndao M. High-yield amplification of Cryptosporidium parvum in interferon gamma receptor knockout mice. Parasitology 2008; 135:1151 - 6; http://dx.doi.org/10.1017/S0031182008004757; PMID: 18667105
   PubMed Web of Science ®Google Scholar
• Cai X, Woods KM, Upton SJ, Zhu G. Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro. Antimicrob Agents Chemother 2005; 49:4437 - 42; http://dx.doi.org/10.1128/AAC.49.11.4437-4442.2005; PMID: 16251280
   PubMed Web of Science ®Google Scholar
• Stauffer W, Ravdin JI. Entamoeba histolytica: an update. Curr Opin Infect Dis 2003; 16:479 - 85; http://dx.doi.org/10.1097/00001432-200310000-00016; PMID: 14502002
   PubMed Web of Science ®Google Scholar
• Stanley SL Jr.. Amoebiasis. Lancet 2003; 361:1025 - 34; http://dx.doi.org/10.1016/S0140-6736(03)12830-9; PMID: 12660071
   PubMed Web of Science ®Google Scholar
• Pritt BS, Clark CG. Amebiasis. Mayo Clin Proc 2008; 83:1154 - 9, quiz 1159-60; http://dx.doi.org/10.4065/83.10.1154; PMID: 18828976
   PubMed Web of Science ®Google Scholar
• Reynolds JEF. Martindale: The Extra Pharmacopoeia, 30th ed. Pharmaceutical Press, London, 1993:516-21.
   Google Scholar
• Haque R, Huston CD, Hughes M, Houpt E, Petri WA Jr.. Amebiasis. N Engl J Med 2003; 348:1565 - 73; http://dx.doi.org/10.1056/NEJMra022710; PMID: 12700377
   PubMed Web of Science ®Google Scholar
• Buckner FS, Waters NC, Avery VM. Recent highlights in anti-protozoan drug development and resistance research. Int J Parasitol: Drugs and Drug Res 2012; In press http://dx.doi.org/10.1016/j.ijpddr.2012.05.002
   Google Scholar
• Giannini EH, Brewer EJ Jr., Kuzmina N, Shaikov A, Wallin B, The USA Pediatric Rheumatology Collaborative Study Group. The USSR Cooperative Children’s Study Group. Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. Arthritis Rheum 1990; 33:466 - 76; http://dx.doi.org/10.1002/art.1780330402; PMID: 2183804
   PubMed Web of Science ®Google Scholar
• Gottlieb NL. Pharmacology of auranofin: overview and update. Scand J Rheumatol Suppl 1986; 63:19 - 28; PMID: 3110942
   PubMedGoogle Scholar
• Griggs RC, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J, et al, Rare Diseases Clinical Research Network. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab 2009; 96:20 - 6; http://dx.doi.org/10.1016/j.ymgme.2008.10.003; PMID: 19013090
   PubMed Web of Science ®Google Scholar
• Wellman-Labadie O, Zhou Y. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?. Health Policy 2010; 95:216 - 28; http://dx.doi.org/10.1016/j.healthpol.2009.12.001; PMID: 20036435
   PubMed Web of Science ®Google Scholar
• Cheung RY, Cohen JC, Illingworth P. Orphan drug policies: implications for the United States, Canada, and developing countries. Health Law J 2004; 12:183 - 200; PMID: 16539081
   PubMedGoogle Scholar
• Blower MD, Nachury M, Heald R, Weis KA. A Rae1-containing ribonucleoprotein complex is required for mitotic spindle assembly. Cell 2005; 121:223 - 34; http://dx.doi.org/10.1016/j.cell.2005.02.016; PMID: 15851029
   PubMed Web of Science ®Google Scholar
• Parks RE Jr., Brown PR, Cheng YC, Agarwal KC, Kong CM, Agarwal RP, et al. Purine metabolism in primitive erythrocytes. Comp Biochem Physiol B 1973; 45:355 - 64; http://dx.doi.org/10.1016/0305-0491(73)90070-9; PMID: 4351428
   PubMed Web of Science ®Google Scholar
• Simon TM, Kunishima DH, Vibert GJ, Lorber A. Screening trial with the coordinated gold compound auranofin using mouse lymphocyte leukemia P388. Cancer Res 1981; 41:94 - 7; PMID: 6778607
   PubMed Web of Science ®Google Scholar
• Sok J, Calfon M, Lu J, Lichtlen P, Clark SG, Ron D. Arsenite-inducible RNA-associated protein (AIRAP) protects cells from arsenite toxicity. Cell Stress Chaperones 2001; 6:6 - 15; http://dx.doi.org/10.1379/1466-1268(2001)006<0006:AIRAPA>2.0.CO;2; PMID: 11525245
   PubMed Web of Science ®Google Scholar
• Rigobello MP, Scutari G, Boscolo R, Bindoli A. Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative. Br J Pharmacol 2002; 136:1162 - 8; http://dx.doi.org/10.1038/sj.bjp.0704823; PMID: 12163349
   PubMed Web of Science ®Google Scholar
• Omata Y, Folan M, Shaw M, Messer RL, Lockwood PE, Hobbs D, et al. Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1). Toxicol In Vitro 2006; 20:882 - 90; http://dx.doi.org/10.1016/j.tiv.2006.01.012; PMID: 16510263
   PubMed Web of Science ®Google Scholar
• Lu J, Chew EH, Holmgren A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A 2007; 104:12288 - 93; http://dx.doi.org/10.1073/pnas.0701549104; PMID: 17640917
   PubMed Web of Science ®Google Scholar
• Angelucci F, Sayed AA, Williams DL, Boumis G, Brunori M, Dimastrogiovanni D, et al. Inhibition of Schistosoma mansoni thioredoxin-glutathione reductase by auranofin: structural and kinetic aspects. J Biol Chem 2009; 284:28977 - 85; http://dx.doi.org/10.1074/jbc.M109.020701; PMID: 19710012
   PubMed Web of Science ®Google Scholar
• Leitsch D, Kolarich D, Wilson IB, Altmann F, Duchêne M. Nitroimidazole action in Entamoeba histolytica: a central role for thioredoxin reductase. PLoS Biol 2007; 5:e211; http://dx.doi.org/10.1371/journal.pbio.0050211; PMID: 17676992
   PubMedGoogle Scholar
• Brown DM, Upcroft JA, Edwards MR, Upcroft P. Anaerobic bacterial metabolism in the ancient eukaryote Giardia duodenalis. Int J Parasitol 1998; 28:149 - 64; http://dx.doi.org/10.1016/S0020-7519(97)00172-0; PMID: 9504342
   PubMed Web of Science ®Google Scholar
• Mondal D, Haque R, Sack RB, Kirkpatrick BD, Petri WA Jr.. Attribution of malnutrition to cause-specific diarrheal illness: evidence from a prospective study of preschool children in Mirpur, Dhaka, Bangladesh. Am J Trop Med Hyg 2009; 80:824 - 6; PMID: 19407131
   PubMed Web of Science ®Google Scholar
• Busatti HG, Santos JF, Gomes MA. The old and new therapeutic approaches to the treatment of giardiasis: where are we?. Biologics 2009; 3:273 - 87; PMID: 19707415
   PubMedGoogle Scholar
• Cacciò SM, Ryan U. Molecular epidemiology of giardiasis. Mol Biochem Parasitol 2008; 160:75 - 80; http://dx.doi.org/10.1016/j.molbiopara.2008.04.006; PMID: 18501440
   PubMed Web of Science ®Google Scholar